Vimarsana
Biggest News Aggregation in the World

Cs Microinjector News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cs Microinjector. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cs Microinjector Today - Breaking & Trending Today

Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2023 Earnings Call Transcript - Vimarsana News

Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2023 Earnings Call Transcript

Published: March 13, 2024

Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2023 Earnings Call Transcript March 13, 2024 Clearside Biomedical, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and welcome to the Clearside Biomedical Q4 2023 Financial Results and Corporate Update Call. At this […]

Source: yahoo.com
Related Topics:
Asia PacificCharlie DeignanGeorge LasezkayBiocryst PharmaceuticalsArctic VisionNeedham Healthcare ConferenceLife ScienceCharitable CountriesEarthquake Prone CountriesClearside BiomedicalJenny KobinLearside Investor RelationsGeorge LasezkayForward Looking StatementsCs MicroinjectorClearside BiomedicalBiocryst PharmaceuticalsClinical Trial
Clearside Biomedical Inc (CLSD) Reports Significant Licensing Revenue Growth in Q4 and Full ... - Vimarsana News

Clearside Biomedical Inc (CLSD) Reports Significant Licensing Revenue Growth in Q4 and Full ...

Published: March 12, 2024

Licensing Deals Propel Revenue as Company Advances Clinical Trials

Source: yahoo.com
Related Topics:
Clearside Biomedical IncBiocryst PharmaceuticalsFinancial PerformanceClearside BiomedicalBiomedical IncBiocryst PharmaceuticalsClearside BiomedicalCs MicroinjectorLicense FeeLicense Revenue
Clearside Biomedical Positive OASIS and Extension Study - Vimarsana News

Clearside Biomedical Positive OASIS and Extension Study

Published: October 16, 2023

- Excellent Safety Profile, Stable Vision, and Reduced Frequency of Injections Observed for up to 6 months – - ODYSSEY Phase 2b Clinical Trial...

Source: globenewswire.com
Related Topics:
United StatesGeorge LasezkayDavidm BrownRemy BernardaRahul KhuranaJenny KobinClearside Biomedical IncExchange CommissionRetina SocietyRetina InternationalSafety ProfileStable VisionReduced FrequencyInjections ObservedClinical Trial EnrollmentData ExpectedAnnual ScientificSuprachoroidal InjectionPersistent Activity FollowingRetina ConsultantsExtension StudyChief ExecutiveDiabetic RetinopathyTolerability ResultsAll Cohorts